In a multi-institution database of patients with RET-rearranged NSCLC BM treated with multi-kinase inhibitors (including but not limited to cabozantinib, vandetanib, sunitinib, ponatinib, vandetanib, and alectinib), Drilon et al. This evidence concerns the gene RET and non-small cell lung carcinoma.